Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase II Study of Panobinostat in Paediatric, Adolescent and Young Adult Patients with Solid Tumours Including Osteosarcoma, Malignant Rhabdoid Tumour/Atypical Teratoid Rhabdoid Tumours and Neuroblastoma
Other Non-Commercial Sponsor
National Health & Medical Research Council (NHMRC)
Summary
Participants in this trial will be stratified according to their diagnosis; osteosarcoma, neuroblastoma and MRT/ATRT. Patients will be enrolled following the end of their conventional therapy, which may include chemotherapy and/or radiation treatment. Patients will have a three-week wash out period before commencing on the trial.
Pabinostat will be administered as a continuous daily oral dose, and will follow a dose escalation scheme for each stratum, determined by biological effect of the drug. The final dose will be defined when significant biological effect is achieved with acceptable toxicity, and is maintained for a 4 week period.